By Kosaku Narioka
Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know:
NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period.
REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows.
Shares have gained 3.2% so far this year after rising a 3.1% in 2024.
WHAT TO WATCH:
--Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs.
--Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion.
--Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
May 07, 2025 07:11 ET (11:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.